Endava Receives NYSE Noncompliance Notice as 20-F Restatement Delays Filing
DAVA is trading near its 52-week low of $1.16 (1.7% above the low).
Summary
Endava received an NYSE notice that it is not in compliance with the exchange's timely-filing rule because its fiscal 2026 annual report is late amid an accounting restatement. The company has six months to file and regain compliance, and says it is in talks with lenders about its revolving credit facility.
Key Events · Legal and Risk Events · DAVA
-
NYSE Noncompliance Notice Received
On November 18, 2026, the NYSE notified Endava that it is not in compliance with Section 802.01E because its fiscal 2026 Form 20-F was not filed by the November 17, 2026 due date.
-
Six-Month Cure Period
Endava has up to six months from November 17, 2026 to file the annual report and regain compliance; failing that, the NYSE may grant another six months or begin suspension and delisting proceedings.
-
Restatement Scope Reaffirmed
Adjustments to fiscal 2026 revenue are still estimated at approximately 2%-4% of fiscal 2025 revenue, with no expected adjustment to fiscal 2025 or prior fiscal years.
-
Lender Discussions Underway
Management is in discussions with its lenders as it evaluates the potential impact of these matters on the company's revolving credit facility.
Analysis · DAVA · Technology
The NYSE notice formalizes Endava's noncompliance with the exchange's timely-filing rule, a mechanical consequence of the accounting investigation that has held up its fiscal 2026 annual report. No immediate delisting looms, given the six-month cure window to November 2027, but the notice hard-codes a deadline onto a restatement that remains unfinished. Two details carry more weight than the notice itself: management is now in talks with lenders about the revolving credit facility, putting the balance sheet in play, and the revenue hit is still estimated at roughly 2%-4% of fiscal 2025 revenue with no prior-year restatement. With the stock near its 52-week low, the market is already pricing distress; the open question is whether the credit facility survives the restatement intact.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DAVA was trading at $1.18 on NYSE in the Technology sector, with a market capitalization of approximately $71.4M. The 52-week trading range was $1.16 to $7.18. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.